Want to see TSE:RVV full AI Analyst Report?
RVV Stock Chart & Stats
C$0.02
<C$0.01(20.00%)
At close: 4:00 PM EDT
C$0.02
<C$0.01(20.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.08
Previous CloseN/A
Volume3.00K
Average Volume (3M)285.50K
Market Cap
C$10.46M
Enterprise ValueC$13.12M
Total Cash (Recent Filing)C$22.66K
Total Debt (Recent Filing)C$70.77K
Price to Earnings (P/E)―
Beta-1.51
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low absolute debt reduces fixed financing obligations and interest burden for a development-stage biotech. This structural flexibility helps preserve runway and strategic optionality for partnerships or licensing, decreasing bankruptcy risk versus highly leveraged peers.
Focused R&D PipelineA concentrated business model around psilocybin and repurposed therapeutics creates focused scientific and commercial pathways. Specialization supports targeted trial strategies, clearer partner/asset monetization routes, and alignment with growing institutional interest in psychedelic and repurposing R&D.
Improving Cash BurnA materially smaller operating cash outflow in the trailing twelve months suggests recent cost control or program pacing. Sustained lower burn can extend runway, reduce near-term financing frequency, and improve the company's ability to execute discrete development milestones before raising additional capital.
Bears Say
No RevenueThe company remains pre-revenue with no commercial sales to absorb costs. Without an identifiable revenue stream, management must rely on external financing to fund R&D, creating persistent dilution and execution risk until a product is commercialized or partnered.
Negative Shareholders' EquityNegative equity reflects accumulated losses and reduced balance sheet resilience. This structural weakness can limit borrowing capacity, complicate partnerships, and increase the probability of equity raises or recapitalization, constraining long-term strategic flexibility.
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates dependence on financing to sustain operations. Even with recent improvement, the structural need for external capital raises dilution risk and can delay or derail development timelines if funding windows tighten.
Revive Therapeutics News
RVV FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <C$0.01 and its highest was C$0.08 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is C$10.46M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is Oct 26, 2026 which is in 85 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Revive Therapeutics Ltd released its earnings results on Jun 01, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Revive Therapeutics Ltd reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in TSE:RVV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.